Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 27, 2023SHILAP Revista de lepidopterologíaOpen Access

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety

View Full Paper
Ask AI
Bookmark
Share

Authors

Srđan Verstovšek
Srđan VerstovšekUppsala UniversityRMRuben A. MesaUniversity of InsubriaRLRobert A. LivingstonIncyte (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Verstovšek et al. (2023) studied this question.

synapsesocial.com/papers/69dff21c2c052bbf722554afhttps://doi.org/10.1186/s13045-023-01471-z
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing2013 · 63 citations
  2. 2Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies2022 · 18 citations
  3. 3A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia2019 · 70 citations
  4. 4Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels2018 · 27 citations
  5. 5Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios2021 · 13 citations